Seek Returns logo

JNJ vs. LIN: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at JNJ and LIN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolJNJLIN
Company NameJohnson & JohnsonLinde plc
CountryUnited StatesUnited Kingdom
GICS SectorHealth CareMaterials
GICS IndustryPharmaceuticalsChemicals
Market Capitalization448.07 billion USD222.46 billion USD
ExchangeNYSENasdaqGS
Listing DateJanuary 2, 1962June 17, 1992
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of JNJ and LIN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

JNJ vs. LIN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolJNJLIN
5-Day Price Return4.94%0.18%
13-Week Price Return21.39%1.24%
26-Week Price Return14.65%2.94%
52-Week Price Return14.88%-0.94%
Month-to-Date Return4.66%-0.69%
Year-to-Date Return28.21%13.45%
10-Day Avg. Volume10.00M1.87M
3-Month Avg. Volume8.38M1.75M
3-Month Volatility18.45%12.74%
Beta0.370.93

Profitability

Return on Equity (TTM)

JNJ

30.39%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 30.39% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

LIN

17.46%

Chemicals Industry

Max
29.52%
Q3
13.18%
Median
6.53%
Q1
1.35%
Min
-11.86%

In the upper quartile for the Chemicals industry, LIN’s Return on Equity of 17.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

JNJ vs. LIN: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Net Profit Margin (TTM)

JNJ

25.00%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

A Net Profit Margin of 25.00% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

LIN

20.20%

Chemicals Industry

Max
20.20%
Q3
9.15%
Median
3.94%
Q1
0.60%
Min
-10.43%

A Net Profit Margin of 20.20% places LIN in the upper quartile for the Chemicals industry, signifying strong profitability and more effective cost management than most of its peers.

JNJ vs. LIN: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Operating Profit Margin (TTM)

JNJ

30.18%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

An Operating Profit Margin of 30.18% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

LIN

26.75%

Chemicals Industry

Max
27.33%
Q3
13.82%
Median
7.98%
Q1
3.60%
Min
-7.61%

An Operating Profit Margin of 26.75% places LIN in the upper quartile for the Chemicals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

JNJ vs. LIN: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Profitability at a Glance

SymbolJNJLIN
Return on Equity (TTM)30.39%17.46%
Return on Assets (TTM)12.16%8.10%
Net Profit Margin (TTM)25.00%20.20%
Operating Profit Margin (TTM)30.18%26.75%
Gross Profit Margin (TTM)67.98%48.45%

Financial Strength

Current Ratio (MRQ)

JNJ

1.01

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

JNJ’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

LIN

0.93

Chemicals Industry

Max
3.72
Q3
2.38
Median
1.69
Q1
1.42
Min
0.75

LIN’s Current Ratio of 0.93 falls into the lower quartile for the Chemicals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

JNJ vs. LIN: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

JNJ

0.65

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

JNJ’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

LIN

0.67

Chemicals Industry

Max
1.53
Q3
1.00
Median
0.69
Q1
0.41
Min
0.00

LIN’s Debt-to-Equity Ratio of 0.67 is typical for the Chemicals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

JNJ vs. LIN: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Interest Coverage Ratio (TTM)

JNJ

34.01

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

LIN

33.09

Chemicals Industry

Max
56.43
Q3
26.33
Median
8.84
Q1
2.54
Min
-9.39

LIN’s Interest Coverage Ratio of 33.09 is in the upper quartile for the Chemicals industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

JNJ vs. LIN: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Financial Strength at a Glance

SymbolJNJLIN
Current Ratio (MRQ)1.010.93
Quick Ratio (MRQ)0.680.70
Debt-to-Equity Ratio (MRQ)0.650.67
Interest Coverage Ratio (TTM)34.0133.09

Growth

Revenue Growth

JNJ vs. LIN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

JNJ vs. LIN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

JNJ

2.72%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

JNJ’s Dividend Yield of 2.72% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

LIN

1.25%

Chemicals Industry

Max
6.59%
Q3
3.67%
Median
2.44%
Q1
1.36%
Min
0.00%

LIN’s Dividend Yield of 1.25% is in the lower quartile for the Chemicals industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

JNJ vs. LIN: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Dividend Payout Ratio (TTM)

JNJ

53.34%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

JNJ’s Dividend Payout Ratio of 53.34% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

LIN

40.71%

Chemicals Industry

Max
192.00%
Q3
108.95%
Median
57.38%
Q1
27.28%
Min
0.00%

LIN’s Dividend Payout Ratio of 40.71% is within the typical range for the Chemicals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

JNJ vs. LIN: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Dividend at a Glance

SymbolJNJLIN
Dividend Yield (TTM)2.72%1.25%
Dividend Payout Ratio (TTM)53.34%40.71%

Valuation

Price-to-Earnings Ratio (TTM)

JNJ

19.60

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

JNJ’s P/E Ratio of 19.60 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

LIN

32.60

Chemicals Industry

Max
49.43
Q3
32.03
Median
21.32
Q1
14.93
Min
8.66

A P/E Ratio of 32.60 places LIN in the upper quartile for the Chemicals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

JNJ vs. LIN: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Price-to-Sales Ratio (TTM)

JNJ

4.90

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

JNJ’s P/S Ratio of 4.90 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

LIN

6.58

Chemicals Industry

Max
3.90
Q3
2.23
Median
1.00
Q1
0.55
Min
0.15

With a P/S Ratio of 6.58, LIN trades at a valuation that eclipses even the highest in the Chemicals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

JNJ vs. LIN: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Price-to-Book Ratio (MRQ)

JNJ

4.68

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

JNJ’s P/B Ratio of 4.68 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

LIN

5.73

Chemicals Industry

Max
5.01
Q3
2.59
Median
1.50
Q1
0.95
Min
0.30

At 5.73, LIN’s P/B Ratio is at an extreme premium to the Chemicals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

JNJ vs. LIN: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Chemicals industry benchmarks.

Valuation at a Glance

SymbolJNJLIN
Price-to-Earnings Ratio (TTM)19.6032.60
Price-to-Sales Ratio (TTM)4.906.58
Price-to-Book Ratio (MRQ)4.685.73
Price-to-Free Cash Flow Ratio (TTM)23.9543.18